Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015 (2015), Article ID 627674, 13 pages
http://dx.doi.org/10.1155/2015/627674
Review Article

Anti-VEGF Therapy and the Retina: An Update

1The Royal Berkshire NHS Foundation Trust, Craven Road, Reading RG1 5AN, UK
2Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK
3St George’s University of London, Cranmer Terrace, London SW17 0RE, UK

Received 16 March 2015; Revised 28 June 2015; Accepted 5 July 2015

Academic Editor: Tamer A. Macky

Copyright © 2015 Vikas Tah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Rajappa, P. Saxena, and J. Kaur, “Ocular angiogenesis: mechanisms and recent advances in therapy,” Advances in Clinical Chemistry, vol. 50, pp. 103–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. PMLive, “Top Pharma list,” November 2014, http://www.pmlive.com/top_pharma_list/Top_50_pharmaceutical_products_by_global_sales.
  3. J. G. Arroyo, “Towards a rational approach to combination therapy for neovascular age related macular degeneration,” The British Journal of Ophthalmology, vol. 91, no. 2, pp. 130–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. W. Miller, A. P. Adamis, D. T. Shima et al., “Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model,” American Journal of Pathology, vol. 145, no. 3, pp. 574–584, 1994. View at Google Scholar · View at Scopus
  5. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. M. S. Gordon, K. Margolin, M. Talpaz et al., “Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 843–850, 2001. View at Google Scholar · View at Scopus
  7. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. A. J. Augustin, “Change of treatment paradigms for wet age-related macular degeneration,” Clinical & Experimental Immunology, vol. 121, pp. 458–465, 2000. View at Google Scholar
  9. P. J. Rosenfeld, A. A. Moshfeghi, and C. A. Puliafito, “Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 331–335, 2005. View at Google Scholar · View at Scopus
  10. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. W. Stewart, P. J. Rosenfeld, F. M. Penha et al., “Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye),” Retina, vol. 32, no. 3, pp. 434–457, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. Centers for Disease Control and Prevention, “Blindness caused by diabetes—Massachusetts, 1987–1994,” The Journal of the American Medical Association, vol. 276, no. 23, pp. 1865–1866, 1996. View at Publisher · View at Google Scholar
  14. E. Prokofyeva and E. Zrenner, “Epidemiology of major eye diseases leading to blindness in Europe: a literature review,” Ophthalmic Research, vol. 47, no. 4, pp. 171–188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Ford, N. Lois, P. Royle, C. Clar, D. Shyangdan, and N. Waugh, “Current treatments in diabetic macular oedema: systematic review and meta-analysis,” British Medical Journal Open, vol. 3, no. 2, Article ID e002269, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. National Institute for Health and Clinical Excellence (NICE), “Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237),” April 2013, http://www.nice.org.uk/guidance/ta274.
  17. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar
  18. Diabetic Retinopathy Clinical Research Network, “Expanded 2-year follow-up of Ranibizumab plus prompt or deferred laser or Triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 609–614, 2011. View at Publisher · View at Google Scholar
  19. P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. V. Do, Q. D. Nguyen, A. A. Khwaja et al., “Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment,” JAMA Ophthalmology, vol. 131, no. 2, pp. 139–145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. D. V. Do, J. S. Heier, S. M. Shah et al., “Two-year results of the READ 2 study: ranibizumab for edema of the macula in diabetes,” Investigative Ophthalmology & Visual Science, vol. 51, no. 5, pp. 5842–5847, 2010. View at Google Scholar
  22. RISE and RIDE Research Group, “Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE,” Ophthalmology, vol. 119, no. 4, pp. 789–801, 2012. View at Google Scholar
  23. Decision Support Unit, “Bevacizumab in eye conditions: issues related to quality, use, efficacy and safety,” 2012, http://www.nicedsu.org.uk/Bevacizumab%20report%20-%20NICE%20published%20version%2011.04.13.pdf.
  24. R. Rajendram, S. Fraser-Bell, A. Kaines et al., “A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-Month data: report 3,” Archives of Ophthalmology, vol. 130, no. 8, pp. 972–979, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. D. V. Do, Q. D. Nguyen, D. Boyer et al., “One-year outcomes of the da Vinci study of VEGF trap-eye in eyes with diabetic macular edema,” Ophthalmology, vol. 119, no. 8, pp. 1658–1665, 2012. View at Google Scholar
  26. J.-F. Korobelnik, D. V. Do, U. Schmidt-Erfurth et al., “Intravitreal aflibercept for diabetic macular edema,” Ophthalmology, vol. 121, no. 11, pp. 2247–2254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. The Diabetic Retinopathy Clinical Research Network, “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema,” The New England Journal of Medicine, vol. 372, pp. 1193–1203, 2015. View at Publisher · View at Google Scholar
  28. National Institute for Health and Care Excellence (NICE), “Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271),” 2013, http://www.nice.org.uk/guidance/ta301/.
  29. G. Virgili, M. Parravano, F. Menchini, and J. R. Evans, “Anti-vascular endothelial growth factor for diabetic macular oedema,” The Cochrane Database of Systematic Reviews, vol. 10, 2014. View at Publisher · View at Google Scholar
  30. S. Goyal, M. Lavalley, and M. L. Subramanian, “Meta-analysis and review on the effect of bevacizumab in diabetic macular edema,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 1, pp. 15–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. Royal College of Ophthalmology, “Diabetic Retinopathy Guidelines,” July 2013, https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-301-FINAL-DR-GUIDELINES-DEC-2012-updated-July-2013.pdf.
  32. Q. T. Ho and C. J. Kuo, “Vascular endothelial growth factor: biology and therapeutic applications,” The International Journal of Biochemistry & Cell Biology, vol. 39, no. 7-8, pp. 1349–1357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study,” Ophthalmology, vol. 116, no. 1, pp. 57.e5–65.e5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Abraham, H. Yue, and L. Wilson, “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2,” American Journal of Ophthalmology, vol. 150, no. 3, pp. 315.e1–324.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. U. Schmidt-Erfurth, B. Eldem, R. Guymer et al., “Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study,” Ophthalmology, vol. 118, no. 5, pp. 831–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43–58.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. F. G. Holz, W. Amoaku, J. Donate et al., “Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study,” Ophthalmology, vol. 118, no. 4, pp. 663–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. B. G. Busbee, A. C. Ho, D. M. Brown et al., “Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration,” Ophthalmology, vol. 120, no. 5, pp. 1046–1056, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Engelbert, S. A. Zweifel, and K. B. Freund, “Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified ‘treat and extend’ dosing regimen of intravitreal antivascular endothelial growth factor therapy,” Retina, vol. 30, no. 9, pp. 1368–1375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Engelbert, S. A. Zweifel, and K. B. Freund, “‘treat and extend’ dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation,” Retina, vol. 29, no. 10, pp. 1424–1431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. D. F. Martin, M. G. Maguire, G. S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar
  42. U. Chakravarthy, S. P. Harding, C. A. Rogers et al., “Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial,” The Lancet, vol. 382, no. 9900, pp. 1258–1267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. U. Schmidt-Erfurth, P. K. Kaiser, J.-F. Korobelnik et al., “Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies,” Ophthalmology, vol. 121, no. 1, pp. 193–201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. J. S. Heier, D. M. Brown, V. Chong et al., “Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration,” Ophthalmology, vol. 119, pp. 2537–2548, 2012. View at Publisher · View at Google Scholar
  45. M. J. Tolentino, A. Dennrick, E. John, and M. S. Tolentino, “Drugs in phase II clinical trials for the treatment of age-related macular degeneration,” Expert Opinion on Investigational Drugs, vol. 24, no. 2, pp. 183–199, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. P. U. Dugel, “Phase 2b clinical trial of Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMO),” in Proceedings of the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting, American Academy of Ophthalmology (AAO), November 2012.
  47. D. H. Orth and A. Patz, “Retinal branch vein occlusion,” Survey of Ophthalmology, vol. 22, no. 6, pp. 357–376, 1978. View at Publisher · View at Google Scholar
  48. The Branch Vein Occlusion Study Group, “Argon laser photocoagulation for macular edema in branch vein occlusion,” American Journal of Ophthalmology, vol. 98, no. 3, pp. 271–282, 1984. View at Google Scholar
  49. G. Coscas, A. Loewenstein, A. Augustin et al., “Management of retinal vein occlusion—consensus document,” Ophthalmologica, vol. 226, no. 1, pp. 4–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Laouri, E. Chen, M. Looman, and M. Gallagher, “The burden of disease of retinal vein occlusion: review of the literature,” Eye, vol. 25, no. 8, pp. 981–988, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. J.-D. Ho, C.-Y. Tsai, S.-W. Liou, R. J.-F. Tsai, and H.-C. Lin, “Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan,” American Journal of Ophthalmology, vol. 145, no. 4, pp. 722.3–728.e3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Klein, S. E. Moss, S. M. Meuer, and B. E. K. Klein, “The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study,” Archives of Ophthalmology, vol. 126, no. 4, pp. 513–518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Rehak and M. Rehak, “Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities,” Current Eye Research, vol. 33, no. 2, pp. 111–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. J. G. Haymore and L. J. Mejico, “Retinal vascular occlusion syndromes,” International Ophthalmology Clinics, vol. 49, no. 3, pp. 63–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Kaur, W. S. Foulds, and E. A. Ling, “Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management,” Progress in Retinal and Eye Research, vol. 27, no. 6, pp. 622–647, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. D. M. Brown, P. A. Campochiaro, R. B. Bhisitkul et al., “Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study,” Ophthalmology, vol. 118, no. 8, pp. 1594–1602, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. D. M. Brown, P. A. Campochiaro, R. P. Singh et al., “Ranibizumab for macular edema following central retinal vein occlusion: six month primary end point results of a phase III study,” Ophthalmology, vol. 117, no. 6, pp. 1124–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Boyer, J. Heier, D. M. Brown et al., “Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 COPERNICUS Study,” Ophthalmology, vol. 119, no. 5, pp. 1024–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. D. M. Brown, “Intravitreal aflibercept injection of central retinal vein occlusions: 2-year results from the COPERNICUS Study,” American Academy of Ophthalmology, vol. 155, no. 3, pp. 429–437, 2012. View at Google Scholar
  60. T. Y. Wong, A. Ferreira, R. Hughes, G. Carter, and P. Mitchell, “Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review,” American Journal of Ophthalmology, vol. 157, no. 1, pp. 9.e12–25.e12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Kanski, Clinical Ophthalmology: A Systematic Approach, Butterworth-Heinemann, 7th edition, 2011.
  62. N. Leveziel, Y. Yu, R. Reynolds et al., “Genetic factors for choroidal neovascularization associated with high myopia,” Investigative Ophthalmology and Visual Science, vol. 53, no. 8, pp. 5004–5009, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Mitry and H. Zambarakji, “Recent trends in the management of maculopathy secondary to pathological myopia,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 1, pp. 3–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Silva, “Myopic maculopathy: a review,” Ophthalmologica, vol. 228, no. 4, pp. 197–213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. H. M. Kang and H. J. Koh, “Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study,” Retina, vol. 33, no. 8, pp. 1613–1622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Y. Wong, K. Ohno-Matsui, N. Leveziel et al., “Myopic choroidal neovascularisation: current concepts and update on clinical management,” British Journal of Ophthalmology, vol. 99, no. 3, pp. 289–296, 2015. View at Publisher · View at Google Scholar
  67. J. B. Gunther and M. M. Altaweel, “Bevacizumab (avastin) for the treatment of ocular disease,” Survey of Ophthalmology, vol. 54, no. 3, pp. 372–400, 2009. View at Publisher · View at Google Scholar
  68. S. Wolf, V. J. Balciuniene, G. Laganovska et al., “RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia,” Ophthalmology, vol. 121, no. 3, pp. 682–692, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Gharbiya, R. Giustolisi, F. Allievi et al., “Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-a randomized controlled trial,” American Journal of Ophthalmology, vol. 149, no. 3, pp. 458–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Y. Y. Lai, F. O. J. Luk, G. K. Y. Lee, and D. S. C. Lam, “Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization,” Eye, vol. 26, no. 7, pp. 1004–1011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Gliem, R. P. Finger, R. Fimmers, C. K. Brinkmann, F. G. Holz, and P. Charbel Issa, “Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review,” Retina, vol. 33, no. 7, pp. 1300–1314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Julián, C. Terrada, C. Fardeau et al., “Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results,” Acta Ophthalmologica, vol. 89, no. 2, pp. 179–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. U. De Benedetto, M. Battaglia Parodi, K. A. Knutsson et al., “Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma,” Journal of Ocular Pharmacology and Therapeutics, vol. 28, no. 5, pp. 550–552, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Rizzo, F. Genovesi-Ebert, E. Bartolo, A. Vento, S. Miniaci, and G. Williams, “Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR),” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 6, pp. 837–842, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Modarres, H. Nazari, K. G. Falavarjani, M. Naseripour, M. Hashemi, and M. M. Parvaresh, “Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy,” European Journal of Ophthalmology, vol. 19, no. 5, pp. 848–852, 2009. View at Google Scholar · View at Scopus
  76. J. F. Arevalo, M. Maia, H. W. Flynn Jr. et al., “Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy,” British Journal of Ophthalmology, vol. 92, no. 2, pp. 213–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. J. O. Mason III, P. A. Nixon, and M. F. White, “Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 142, no. 4, pp. 685–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. A. M. Minnella, C. M. Savastano, L. Ziccardi et al., “Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy,” Acta Ophthalmologica, vol. 86, no. 6, pp. 683–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Moradian, H. Ahmadieh, M. Malihi, M. Soheilian, M. H. Dehghan, and M. Azarmina, “Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 12, pp. 1699–1705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. H. A. Mintz-Hittner, K. A. Kennedy, and A. Z. Chuang, “Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity,” The New England Journal of Medicine, vol. 364, no. 7, pp. 603–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. S. J. Lim, M. I. Roh, and O. W. Kwon, “Intravitreal bevacizumab injection for central serous chorioretinopathy,” Retina, vol. 30, no. 1, pp. 100–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. H. K. Seong, J. H. Bae, E. S. Kim, J. R. Han, W. H. Nam, and H. K. Kim, “Intravitreal bevacizumab to treat acute central serous chorioretinopathy: Short-term effect,” Ophthalmologica, vol. 223, no. 5, pp. 343–347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. B. George, W. J. Wirostko, T. B. Connor, and N. W. Choong, “Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy,” Journal of Thoracic Oncology, vol. 4, no. 5, pp. 661–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. I. C. Kuo, J. A. Haller, R. Maffrand, R. H. Sambuelli, and V. E. Reviglio, “Regression of a subfoveal choroidal metastasis of colorectal carcinoma after intravitreous bevacizumab treatment,” JAMA Ophthalmology, vol. 126, no. 9, pp. 1311–1313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. H.-Y. Yao, C.-T. Horng, J.-T. Chen, and M.-L. Tsai, “Regression of choroidal metastasis secondary to breast carcinoma with adjuvant intravitreal injection of bevacizumab,” Acta Ophthalmologica, vol. 88, no. 7, pp. e282–e283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. J. O. Mason III, M. A. Albert Jr., T. O. Persaud, and R. S. Vail, “Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma,” Retina, vol. 27, no. 7, pp. 903–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. B. R. Lima, L. R. Schoenfield, and A. D. Singh, “The impact of intravitreal bevacizumab therapy on choroidal melanoma,” American Journal of Ophthalmology, vol. 151, no. 2, pp. 323.e2–328.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus